BioCentury | Nov 10, 2017
Company News

Management tracks: Immunomedics, WuXi

...Biologics Inc. (Vancouver, B.C.) appointed Jennifer Archibald CFO. She was chief business operations officer at Cardiome Pharma Corp....
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...nivolumab's label to include treatment of hepatocellular carcinoma in adults previously treated with Nexavar sorafenib Cardiome Pharma Corp....
BioCentury | Sep 1, 2017
Clinical News

FDA refuses NDA for SteadyMed's Trevyent

...performance testing, as well as additional design verification and validation testing. In 2015, SteadyMed granted Cardiome Pharma Corp....
...3, 2015 ). Trevyent is a prostacyclin analog treprostinil delivered via SteadyMed's subcutaneous PatchPump technology. Cardiome Pharma Corp....
...TSX:COM; NASDAQ:CRME), Vancouver, B.C. SteadyMed Ltd. (NASDAQ:STDY), San Ramon, Calif. Product: Trevyent treprostinil Business: Cardiovascular Alicia Parker Trevyent Cardiome Pharma Corp. SteadyMed...
BioCentury | Sep 1, 2017
Clinical News

FDA snubs Cardiome's Brinavess resubmission for AF

...atrial fibrillation (AF) would not be sufficient to support resubmission of an NDA. In 2008, Cardiome...
...result in the need to run an additional trial (see BioCentury, Aug. 18, 2008 ). Cardiome...
...adults. Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME), Vancouver, B.C. Product: IV Brinavess vernakalant (Kynapid, MK-6621) Business: Cardiovascular Alicia Parker Brinavess Kynapid MK-6621 Vernakalant (IV) Cardiome Pharma Corp....
BioCentury | Aug 21, 2017
Company News

FDA snubs Brinavess resubmission for AF

...treat atrial fibrillation would not be sufficient to support resubmission of an NDA. On Monday, Cardiome...
...35%) to C$3.26 in Toronto and fell $1.27 (33%) to $2.60 on NASDAQ. In 2008, Cardiome...
...in the need to run an additional trial (see BioCentury Extra, Aug. 11, 2008) . Cardiome...
BioCentury | Jul 13, 2017
Clinical News

SteadyMed submits NDA for Trevyent to treat PAH

...pulmonary arterial hypertension (PAH). The company hopes to launch the candidate in mid-2018. SteadyMed partner Cardiome Pharma Corp....
...for the product in the EU and Canada by year end. In 2015, SteadyMed granted Cardiome...
...SteadyMed's subcutaneous PatchPump technology. SteadyMed Ltd. (NASDAQ:STDY), San Ramon, Calif. Product: Trevyent treprostinil Business: Cardiovascular Alex Himes Trevyent Cardiome Pharma Corp. SteadyMed...
BioCentury | May 19, 2017
Company News

Management tracks

...CFO at CoLucid Pharmaceuticals Inc. , which Eli Lilly and Co. (NYSE:LLY) acquired. Cardiovascular company Cardiome Pharma Corp....
...named chief business operations officer. Renz was EVP and CFO at Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Cardiome...
BioCentury | Apr 7, 2017
Finance

To market, to market

...NASDAQ:BMRN) Brineura cerliponase alfa Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease PDUFA date 4/27/17 Cardiome Pharma Corp....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...III data 2017 BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) BCX7353 Hereditary angioedema (HAE) Ph II data 1Q17 Cardiome Pharma Corp....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...NASDAQ:ARGS) 7/28/16 $50.0 $226.2 $204.7 -9% Exact Sciences Corp. (NASDAQ:EXAS) 7/28/16 $131.8 $1,654.9 $1,982.7 20% Cardiome Pharma Corp....
Items per page:
1 - 10 of 360
BioCentury | Nov 10, 2017
Company News

Management tracks: Immunomedics, WuXi

...Biologics Inc. (Vancouver, B.C.) appointed Jennifer Archibald CFO. She was chief business operations officer at Cardiome Pharma Corp....
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...nivolumab's label to include treatment of hepatocellular carcinoma in adults previously treated with Nexavar sorafenib Cardiome Pharma Corp....
BioCentury | Sep 1, 2017
Clinical News

FDA refuses NDA for SteadyMed's Trevyent

...performance testing, as well as additional design verification and validation testing. In 2015, SteadyMed granted Cardiome Pharma Corp....
...3, 2015 ). Trevyent is a prostacyclin analog treprostinil delivered via SteadyMed's subcutaneous PatchPump technology. Cardiome Pharma Corp....
...TSX:COM; NASDAQ:CRME), Vancouver, B.C. SteadyMed Ltd. (NASDAQ:STDY), San Ramon, Calif. Product: Trevyent treprostinil Business: Cardiovascular Alicia Parker Trevyent Cardiome Pharma Corp. SteadyMed...
BioCentury | Sep 1, 2017
Clinical News

FDA snubs Cardiome's Brinavess resubmission for AF

...atrial fibrillation (AF) would not be sufficient to support resubmission of an NDA. In 2008, Cardiome...
...result in the need to run an additional trial (see BioCentury, Aug. 18, 2008 ). Cardiome...
...adults. Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME), Vancouver, B.C. Product: IV Brinavess vernakalant (Kynapid, MK-6621) Business: Cardiovascular Alicia Parker Brinavess Kynapid MK-6621 Vernakalant (IV) Cardiome Pharma Corp....
BioCentury | Aug 21, 2017
Company News

FDA snubs Brinavess resubmission for AF

...treat atrial fibrillation would not be sufficient to support resubmission of an NDA. On Monday, Cardiome...
...35%) to C$3.26 in Toronto and fell $1.27 (33%) to $2.60 on NASDAQ. In 2008, Cardiome...
...in the need to run an additional trial (see BioCentury Extra, Aug. 11, 2008) . Cardiome...
BioCentury | Jul 13, 2017
Clinical News

SteadyMed submits NDA for Trevyent to treat PAH

...pulmonary arterial hypertension (PAH). The company hopes to launch the candidate in mid-2018. SteadyMed partner Cardiome Pharma Corp....
...for the product in the EU and Canada by year end. In 2015, SteadyMed granted Cardiome...
...SteadyMed's subcutaneous PatchPump technology. SteadyMed Ltd. (NASDAQ:STDY), San Ramon, Calif. Product: Trevyent treprostinil Business: Cardiovascular Alex Himes Trevyent Cardiome Pharma Corp. SteadyMed...
BioCentury | May 19, 2017
Company News

Management tracks

...CFO at CoLucid Pharmaceuticals Inc. , which Eli Lilly and Co. (NYSE:LLY) acquired. Cardiovascular company Cardiome Pharma Corp....
...named chief business operations officer. Renz was EVP and CFO at Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Cardiome...
BioCentury | Apr 7, 2017
Finance

To market, to market

...NASDAQ:BMRN) Brineura cerliponase alfa Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease PDUFA date 4/27/17 Cardiome Pharma Corp....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...III data 2017 BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) BCX7353 Hereditary angioedema (HAE) Ph II data 1Q17 Cardiome Pharma Corp....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...NASDAQ:ARGS) 7/28/16 $50.0 $226.2 $204.7 -9% Exact Sciences Corp. (NASDAQ:EXAS) 7/28/16 $131.8 $1,654.9 $1,982.7 20% Cardiome Pharma Corp....
Items per page:
1 - 10 of 360